CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Conduct Clinical Studies on Oral Nicotine Delivery Utilizing DehydraTECH Absorption Platform
Lexaria Nicotine LLC, a subsidiary of Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), recently secured research and development (“R&D”) funding in exchange for equity and licensing rights. Utilizing its DehydraTECH absorption platform, Lexaria will execute a wide-ranging series of clinical studies on oral forms of nicotine delivery. A recent article discussing the company reads, “Under an investment agreement by its wholly owned subsidiary, Lexaria Nicotine LLC, a partner, will provide $1 million toward research on nicotine consumer products that use DehydraTECH(TM)http://cnw.fm/DnlA2. . . Lexaria’s partner will receive certain licensing rights to commercialize these DehydraTECH products exclusively in the United States and…